Jazz Pharmaceuticals to acquire Celator in $1.5 billion deal
May 31, 2016Manufacturing and Production, Sales and Marketing $1.5 billion, Vyxeos, acquisition, celator, jazz, leukaemia, merger, oncology
Jazz Pharmaceuticals (NASDAQ: JAZZ) has announced that it has entered into a definitive merger agreement with Celator Pharmaceuticals (NASDAQ: CPXX) …
Weekly Movers: XenoPort, Akari, Bayer…
May 31, 2016Manufacturing and Production, Research and Development, Sales and Marketing Bayer, Sarepta Therapeutics, Stick Market, Stock, Xenoport, finance
Bayer-Monsanto story comes close on the heels of Sanofi-Medivation tussle as the pharma sector goes through the motions of consolidation. …
Genmab receives milestone payment for first Darzalex sale in Europe
May 31, 2016Manufacturing and Production, Sales and Marketing EU, FDA, Janssen, commercial, commercialised, daratumumab, darzalex, genman, multiple myeloma, sale, sales
Genmab (NASDAQ: GEN) has announced that the company is set to receive a milestone payment of $30 million from its …
EU green-lights Samsung Bioepis, Biogen’s Remicade biosimilar Flixabi
May 31, 2016Manufacturing and Production, Research and Development, Sales and Marketing Biogen, Samsung Bioepis, biosimilar, drug trial, regulation, research
Samsung Bioepis and partner Biogen (Nasdaq: BIIB) said the European Commission has approved Flixabi, a biosimilar version of Johnson & …
Roche’s MabThera gets European approval to treat chronic lymphocytic leukaemia
May 31, 2016Manufacturing and Production Roche, chronic lymphocytic leukaemia, drug approval, regulation
Swiss drugmaker Roche (SIX: ROG) on Tuesday said the European Commission (EC) has approved the subcutaneous (SC) formulation of its …
Uni spin out gets new chariman, CFO, COO
May 27, 2016Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing
Caldan Therapeutics is a spin-out company from the Universities of Glasgow and Southern Denmark which is looking at developing novel …
EMA to revise clinical trial guidelines
May 27, 2016Medical Communications, Research and Development EMA, Guidelines, amend, clinical trial, review, revise
The European Medicines Agency (EMA) has announced that it will conduct a review in an attempt to revise its guidelines …
Shire gets positive opinion from EMA on rare gastrointestinal disease treatment
May 27, 2016Medical Communications, Research and Development, Sales and Marketing CHMP, EMA, Revestive, Shire, gastrointestinal, paediatric, short bowel syndrome, treatment
Shire (LSE: SHP) has announced that it has received a positive opinion from the European Medicines Agency’s (EMA) Committee for …
Roche says comparison study for its Gazyva/ Gazyvaro showed superior progression-free survival in follicular lymphoma
May 27, 2016Medical Communications, Research and Development Comparison Study, Roche, drug trial, follicular lymphoma
Roche (SIX: ROG) on Friday said late-stage comparison trials for its drug to treat a slower form of non-Hodgkin lymphoma …
AstraZeneca says NDA for drug to treat hyperkalaemia gets observations from the US FDA
May 27, 2016Medical Communications, Research and Development AstraZeneca, NDA, US FDA, regulation
UK pharma firm AstraZeneca (LSE: AZN) on Friday said the US Food and Drug Administration (FDA) has issued a complete …
FDA approves first buprenorphine implant for opioid dependence
May 27, 2016Medical Communications, Sales and Marketing FDA, addiction, buprenorphine, dependence, implant, opioid, probuphine
The US Food and Drug Administration (FDA) has approved Probuphine, which is the first buprenorphine implant for the maintenance treatment …
AstraZeneca says its Faslodex shows superiority in comparison study for advanced breast cancer
May 27, 2016Medical Communications, Research and Development, Sales and Marketing AstraZeneca, breast cancer, comparision study, drug trial
UK drugmaker AstraZeneca (LSE: AZN) on Friday said late-stage comparison trials for its drug to treat advanced breast cancer showed …
Sam Eldessouky named new corporate controller at Valeant
May 26, 2016Valeant Pharmaceuticals (NYSE: VRX) has announced that Sam Eldessouky has been named senior vice president and corporate controller. Eldessouky joins …
Nice does not recommend Eli Lilly’s lung cancer drug in draft guidance
May 26, 2016Research and Development, Sales and Marketing Cancer Drugs Fund, Eli Lilly, NICE, lung cancer
The National Institute of Care and Excellence (Nice) did not recommend US drugmaker Eli Lilly’s (NYSE: LLY) Portrazza to treat …
Janssen says its Stelara maintained clinical remission in Crohn’s disease in Phase III trials
May 26, 2016Research and Development, Sales and Marketing Crohn’s disease, Janssen, Stelara, crohn's disease, drug trial
Janssen said its maintenance therapy for Crohn’s disease showed remission for patients in late-stage trials. The company said a significant …
Shares at Sarepta Therapeutics jump after FDA delay in drug approval review
May 26, 2016Research and Development, Sales and Marketing Duchenne Muscular Dystrophy, FDA, Sarepta Therapeutics, approval, delay, delayed announcement, muscular dystrophy, sarepta, treatment
Sarepta Therapeutics (NASDAQ: SRPT) has witnessed a sharp rise in the price of its shares after the US Food and …
US FDA committee recommends approval of Sanofi’s combination therapy for type 2 diabetes
May 26, 2016Research and Development, Sales and Marketing
French drug firm Sanofi (Euronext: SAN) said the US Food and Drug Administration (FDA) advisory committee has recommended the approval …
FDA approves CSL haemophilia A drug
May 26, 2016Sales and Marketing CSL, afstyla, haemophilia a, treatment
CSL (ASX: CSL) has announced that the US Food and Drug Administration (FDA) has approved Afstyla (antihaemophilic factor [recombinant), single …
NICE recommends Jevtana for advanced prostate cancer
May 25, 2016Sales and Marketing Jevtana, NICE, approval, prostate cancer, recommendation
The National Institute for Health and Care Excellence (NICE) has recommended Sanofi Genzyme’s Jevtana (cabazitaxel), in combination with prednisone or …
Sanofi makes move to remove Medivation board; Medivation hits back
May 25, 2016Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Medivation, Sanofi, removal of board, takeover
Sanofi (NYSE: SNY) has taken their proposed takeover of Medivation (NASDAQ: MDVN) up several notches, with the French company filing …
Latest content
NIHR chief scientific adviser visits Huddersfield health innovation campus
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
